甲磺酸阿帕替尼治疗骨肉瘤肺转移患者的临床效果观察  

Clinical efficacy of apatinib mesylate tablets for osteosarcoma pulmonary metastases

作　　者：王彩玲[1] 王俊生[1] 阚随随 杨晓利[1] WANG Cai-ling;WANG Jun-sheng;KAN Sui-sui;YANG Xiao-li(Six Departments of Internal Medicine,Anyang Cancer Hospital,Anyang 455000,China)

机构地区：[1]河南省安阳市肿瘤医院内六科,安阳455000

出　　处：《中国肿瘤临床与康复》2018年第12期1496-1498,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨甲磺酸阿帕替尼治疗骨肉瘤肺转移患者的临床疗效及安全性。方法选取2015年10月至2017年12月间安阳市肿瘤医院收治的14例骨肉瘤肺转移患者,均经组织病理学及影像学确诊。患者均口服甲磺酸阿帕替尼500mg/d,4周后进行疗效评价。结果 14例患者中完全缓解0例,部分缓解7例,稳定2例,进展5例,有效率50. 0%,疾病控制率64. 3%。4例患者出现自发性气胸,1例复发性气胸,采用闭式胸腔引流治疗好转后,继续阿帕替尼治疗。14例患者无进展生存时间(PFS)为1. 8～11. 4个月,中位PFS为4. 3个月。单因素分析显示,出现自发性气胸的4例患者PFS为1. 8～4. 7个月,中位PFS为2. 5个月,未出现气胸的患者PFS为2. 3～11. 4月,中位PFS为6. 4月。两者比较,差异有统计学意义(P <0. 05)。常见不良反应主要为Ⅱ级以下,包括高血压、蛋白尿、手足综合征和骨髓抑制。治疗期间,高血压发生率为57. 1%,蛋白尿为35. 7%,手足综合征为14. 3%,骨髓抑制为14. 3%,腹泻为7. 1%。。结论甲磺酸阿帕替尼治疗骨肉瘤肺转移患者安全有效,不良反应可耐受。Objective To discuss the efficacy and safety of efficacy of apatinib mesylate tablets for lung metastatic osteosarcoma-Methods A total of 14 patients with lung metastatic osteosarcoma who were treated at Anyang Cancer Hospital between October 2015 and December 2017 were selected.All the patients were diagnosed by histopathology and imageological examination.They took orally apatinib mesylate 500mg/ d..Efficacy was analyzed 4weeks after the treatment.Results No one achieved complete response.Seven patients achieved partical response.Stable disease was achieved in 2 patients and progressive disease was observed in 5 patients.The overall response rate (ORR)was 50.0%.The disase control rate (DCR)was 64.3%.Spontaneous pneumothorax occurred in 4 patients and primary pneumothorax occurred in 1 patient. After treated with closed drainage of pleural cavity,the disease was improved and they continued to use apatinib.Univariate analysis showed that progreesion-free,survival (PFS)was 1.8-4.7 months and the median PFS was 2.5 months in patients with spontaneous pneumothorax and 2.3-11.4 and 6.4 months respectively in pa- tients with primary pneumothorax (P <0.05).The common adverse reactions were below grade Ⅱ including hypertension,proteinuria,hand-foot syndrome and myelosuppression.Conclusion Apatinib mesylate tablets can effectively used for osteosarcoma pulmonary metastases and the adverse reactions are tolerable.

关 键 词：甲磺酸阿帕替尼 骨肉瘤 肺转移 

分 类 号：R738.6[医药卫生—肿瘤]